Identification of novel targets for antiangiogenic therapy by comparing the gene expressions of tumor and normal endothelial cells. Issue 5 (19th April 2014)

• Record Type: Journal Article
• Authors: Otsubo, Tsuguteru; Hida, Yasuhiro; Ohga, Noritaka; Sato, Hideshi; Kai, Toshihiro; Matsuki, Yasushi; Takasu, Hideo; Akiyama, Kosuke; Maishi, Nako; Kawamoto, Taisuke; Shinohara, Nobuo; Nonomura, Katsuya; Hida, Kyoko
• Is Part Of: Cancer science. Volume 105:Issue 5(2014:May)
• Page Start: 560
• Page End: 567
• Publication Date: 2014-04-19
• Subjects: Cancer -- Periodicals; Neoplasms -- Periodicals; Research -- Periodicals; Electronic journals; 616.994005
• DOI: 10.1111/cas.12394
• Languages: English
• ISSNs: 1347-9032

Abstract

<abstract abstract-type="main" id="cas12394-abs-0001"> <title> <x xml:space="preserve">Abstract</x> </title> <p>Targeting tumor angiogenesis is an established strategy for cancer therapy. Because angiogenesis is not limited to pathological conditions such as cancer, molecular markers that can distinguish between physiological and pathological angiogenesis are required to develop more effective and safer approaches for cancer treatment. To identify such molecules, we determined the gene expression profiles of murine tumor endothelial cells (mTEC) and murine normal endothelial cells using DNA microarray analysis followed by quantitative reverse transcription–polymerase chain reaction analysis. We identified 131 genes that were differentially upregulated in mTEC. Functional analysis using siRNA‐mediated gene silencing revealed five novel tumor endothelial cell markers that were involved in the proliferation or migration of mTEC. The expression of DEF6 and TMEM176B was upregulated in tumor vessels of human renal cell carcinoma specimens, suggesting that they are potential targets for antiangiogenic intervention for renal cell carcinoma. Comparative gene expression analysis revealed molecular differences between tumor endothelial cells and normal endothelial cells and identified novel tumor endothelial cell markers that may be exploited to target tumor angiogenesis for cancer treatment.</p> </abstract>